2024 PDA Good Aseptic Manufacturing Conference

Assessing EU GMP Annex 1: 264 Days into the Journey

Stuttgart, Germany
Ask a Question Exhibitor Standard Contract Clause
Program Highlights

The agenda is out now!

Related PDA Letter Article: Elevating Sterile Manufacturing authored by our Co-Chair, Simone Biel, Merck.

Dear Colleague,

We are thrilled to announce the upcoming 2024 PDA Good Aseptic Manufacturing Conference scheduled to take place on 15-16 May 2024 in Stuttgart, Germany.

This year's conference will revolve around the theme Assessing EU GMP Annex 1: 264 days into the journey, providing a valuable platform to assess our experiences, identify gaps, process challenges, and explore unresolved questions.

Together, we will delve into the impact of this regulatory change, discussing its implications, but also opportunities for the aseptic manufacturing industry. Our primary objective is to facilitate open and constructive discussions among manufacturers, regulators, and experts from various fields. By sharing our experiences and insights, we aim to collectively address the remaining uncertainties and pave the way for further progress in this critical area.

In addition to evaluating the current situation, we want to encourage forward-thinking and explore future disruptive technologies. Let us collectively imagine a world where risks are minimized to the greatest extent possible. Together, we can shape the future of aseptic manufacturing and contribute to safer products for patients worldwide.

We cordially invite you to be a part of this exceptional event, joining us in Stuttgart for two days of in-depth discussions, networking opportunities, and knowledge exchange. Together, we can create a collaborative and inspiring atmosphere that fosters innovation and drives the industry forward.

Following the conference an additional optional site visit at the Syntegon facility will take place on 17 May 2024 in Crailsheim, Germany.

Save the dates for the 2024 PDA Good Aseptic Manufacturing Conference and stay tuned for further updates. We look forward to your participation and to welcoming you to Stuttgart in May 2024.

Sincerely,

The Co-Chairs

Simone Biel, Merck
Darren Beckett, Fedegari

SCIENTIFIC PROGRAM PLANNING COMMITTEE:

  • Simone Biel, Merck
  • Darren Beckett, Fedegari
  • Richard Denk, SKAN
  • Paul Devuyst, GSK
  • Rainer Glöckler, ten23 heath
  • David Keen, Ecolab
  • Hue Kwon, Samsung Bioepis
  • Peter Makowenskyj, GCon Bio
  • Christina Meissner, AGES
  • Tracy Moore, TM Pharma Group
  • Andrea Salmaso, Stevanato Group
  • Helen Sauter, Vetter Pharma
  • Klaus Ullherr, Syntegon
  • Jessie Lindner, PDA
  • Falk Klar, PDA Europe
  • Caroline Lynar, Manager Programs & Events, PDA Europe
Featured Exhibitors
Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Standard Pricing

Standard Member Price

€ 2.250

GovernmentMember Only

€ 1.080

Health AuthorityMember Only

€ 1.080

Early Career ProfessionalMember Only

€ 1.080

StudentMember Only

€ 1.080

AcademicMember Only

€ 1.080

Non-Member

€ 2.550

See Qualifying Criteria for Member Types.

ALL PRICES IN EURO (EUR), EXCLUDING VAT.

WAYS TO REGISTER: 1. Online Registration   2. registration-europe@pda.org

PDA MEMBERS: Please remember to log in before registering If you come from a Governmental or Health Authority Institution or from an Academic Organization, please contact registration-europe@pda.org before registering.

If you need to apply for a visa to enter the event country, PDA Europe must be informed of this fact at least 4 weeks before the start of the event.

Wednesday, 15 May CEST

  • Registration Open

  • Welcome and Introduction

    Alte Stuttgarter Reithalle

    • Committee Member: Falk Klar, PhD, Parenteral Drug Association

  • Welcome from the Co-Chairs

    Alte Stuttgarter Reithalle

    • Co-Chair: Simone Biel, PhD, Senior Regulatory Consultant, Merck

    • Co-Chair: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

  • Opening Plenary Part I: Advancing Aseptic Manufacturing for Safe Medicines - Lessons Learned and Path Forward

    Alte Stuttgarter Reithalle

    • Moderator: Simone Biel, PhD, Senior Regulatory Consultant, Merck

    Through insightful keynote presentations, interactive discussions, and case studies, participants will explore the challenges and achievements in Annex 1 implementation. Join us for this thought-provoking session as we collectively reflect on the progress made thus far, identify areas for improvement, and lay the groundwork for a harmonized approach to aseptic manufacturing that ensures the continued delivery of safe medicines to patients worldwide.
    • Keynote: Empowering Patients Through Good Aseptic Manufacturing: A Vital Journey Towards Safer Medical Products

      • Presenter: Hussain Jafri, PhD, Executive Director , World Patients Alliance

    • Implementation of EU GMP Annex 1 – Inspection Experiences and Expectations

      • Regulatory Presenter: Christina Meissner, AGES - Austrian Agency for Health and Food Safety

    • Fit for Future: Sterile Manufacture? A Personal View on Revised EU GMP Annex 1

      • Regulatory Presenter: Daniel Mueller, PhD, Head of GMDP-Inspectorate, Regierungspraesidium Tuebingen, Germany

  • Networking Coffee Break, Poster Session & Exhibition

  • Opening Plenary Part II: Advancing Aseptic Manufacturing for Safe Medicines - Lessons Learned and Path Forward

    Alte Stuttgarter Reithalle

    • Moderator: Simone Biel, PhD, Senior Regulatory Consultant, Merck

    Through insightful keynote presentations, interactive discussions, and case studies, participants will explore the challenges and achievements in Annex 1 implementation. Join us for this thought-provoking session as we collectively reflect on the progress made thus far, identify areas for improvement, and lay the groundwork for a harmonized approach to aseptic manufacturing that ensures the continued delivery of safe medicines to patients worldwide.
    • Title to be announced

      • Presenter: Tracy Moore, Director, TM Pharma Group Ltd

    • Annex 1 Implementation: A Case Study of the Sterile Production at F. Hoffmann-La Roche Ltd. Kaiseraugst

    • Interactive Questionnaire Session

    • Q&A, Panel Discussion

      • Moderator: Simone Biel, PhD, Senior Regulatory Consultant, Merck

      • Moderator: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

      • Panelist: Hussain Jafri, PhD, Executive Director , World Patients Alliance

      • Panelist: Tarik Cheema, PhD, End to End Contamination Control Manager, F. Hoffmann-La Roche AG

      • Panelist: Tracy Moore, Director, TM Pharma Group Ltd

      • Panelist: Christina Meissner, AGES - Austrian Agency for Health and Food Safety

      • Panelist: Daniel Mueller, PhD, Head of GMDP-Inspectorate, Regierungspraesidium Tuebingen, Germany

  • Networking Lunch Break & Exhibition

    Saal MARITIM & Lobby Empore

  • Guided Poster Walk

    Lobby Empore

  • Session 1, Track A: Impact of EU GMP Annex 1 on Lyophilization

    Alte Stuttgarter Reithalle

    • Moderator: Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, Stevanato Group

    The new Annex 1 of the GMP introduces new requirements relating to the entire freeze-drying process including product transfer. Now you have the opportunity to dive into the main aspects of the new requirements by the analysis of a senior GMP inspector who worked with the Italian Ministry of Health and the Italian Medicines Agency for more than 20 years. You will also be involved in a case study concerning the development of an Aseptic Process Simulation for lyophilized products, that mimics as closely as possible the routine aseptic manufacturing process with a deep dive into a simulation of lyophilization justified by a scientific and risk-based approach.
    • Requirements for Lyophilization in the New Annex 1

      • Regulatory Presenter: Marisa Delbo, PharmD, Consultant , NA

    • A Better Approach to APS for Lyophilized Products - APS Approach for Freeze-Drying Process Considering Annex 1 Requirements

      • Presenter: Christian Scarpato, Process Engineering Manager, Merck

    • Q&A, Discussion

      • Moderator: Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, Stevanato Group

      • Panelist: Marisa Delbo, PharmD, Consultant , NA

      • Panelist: Christian Scarpato, Process Engineering Manager, Merck

  • Session 1, Track B: Sustainability in Aseptic Manufacturing

    • Moderator: Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

    Sustainability is a core value within the whole industry today and the pharmaceutical industry – aseptic process is not an exception. In this session, we will first give an insight into how design, technology, and innovation will participate in setting up sustainable solutions reducing our global impact on the environment by overviewing big levers e.g. WFI, Steam generation, HVAC, circular economy (Single use and Take-back program). Then focus will be given to Big Data and AI to model material impact assessment. While discussing performance and growth, the success of the industry remains that the only way to continue to supply and deliver sustainably is to deliver safety, and compliance in an efficient way.
    • From Sustainability Ambitions into Action: What About Aseptic Manufacturing?

      • Presenter: Michael Hell, PhD, Head of Environment / Sustainability Healthcare Operations, Merck Healthcare KGaA

    • Can We Have Reliable and Fast Sustainability Impact Assessments? Merging Technology, Innovation, and Sustainability

      • Presenter: Alissa Monk, Sustainability Lead , ten23 health

    • Q&A, Discussion

      • Moderator: Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

      • Panelist: Michael Hell, PhD, Head of Environment / Sustainability Healthcare Operations, Merck Healthcare KGaA

      • Panelist: Alissa Monk, Sustainability Lead , ten23 health

  • Networking Coffee Break, Poster Session & Exhibition

    Saal MARITIM & Lobby Empore

  • Session 2, Track A: Filtration and Closed Systems

    Alte Stuttgarter Reithalle

    • Moderator: Peter J. Makowenskyj, MEng, Director of Design Consulting, G-CON

    At the heart of patient safety, aseptic processing is a critical component of drug product manufacturing and ensuring Integrity of one’s process is paramount. During this session, we will have two subject matter experts on the subject speak about their experiences around filtration and single use assembly integrity. They will assess the impact of regulations and implications on safety as well as extreme process conditions and steps which should be taken to ensure proper compliance.
    • PUPSIT in the Revised Annex I – Friend or Foe of the Pharmaceutical Entrepreneur?

      • Presenter: Manuel Grund, Process Engineer, Roche Pharmaceuticals

    • Contamination Control Strategies in Processing of Frozen Sterile Bulk Drug Product in Single-use Bag Assembly

      • Presenter: Yuan-An Liu, PhD, Associate Director CMC, BioNTech SE

    • Q&A, Discussion

      • Moderator: Peter J. Makowenskyj, MEng, Director of Design Consulting, G-CON

      • Panelist: Manuel Grund, Process Engineer, Roche Pharmaceuticals

      • Panelist: Yuan-An Liu, PhD, Associate Director CMC, BioNTech SE

  • Session 2, Track B: Aseptic Set-Up of Filling Machines

    • Moderator: Klaus Ullherr, Senior Product Manager, Syntegon Technology GmbH

    With the requirements of the new Annex 1, the aseptic set-up of a filling machine gets really challenging. In former times you could use the VHP cycle as the final sterilization step. This is not possible anymore. Indirect product contact parts have to be (ideally steam-) sterilized and installed after the VHP cycle. The track shows two different approaches that are both relevant these days: One with an existing isolator line where you use enhanced “classical” methods to install the steam sterilized parts. And a completely new developed machine with a gloveless isolator. Where you do a steam sterilization for the indirect product contact parts and a fully automatic aseptic transfer and installation by using RTP-ports and a robot. For the filling path both solutions are using pre-sterilized single use filling systems.
    • Implementing Annex 1 Guidelines: A Comprehensive Approach to Sterility Assurance for Indirect Product Contact Parts

      • Presenter: Christian Rust, B.S. Chemical and Biomolecular Engineering, Technical Operations, MSD

    • Compliance with New Annex 1 on a Fill/Finish Machine: A Glance into the Future

      • Presenter: Helen Sauter, Dr, Director Quality Assurance, Vetter Pharma Fertigung GmbH & Co. KG

    • Q&A, Discussion

      • Moderator: Klaus Ullherr, Senior Product Manager, Syntegon Technology GmbH

      • Panelist: Christian Rust, B.S. Chemical and Biomolecular Engineering, Technical Operations, MSD

      • Panelist: Helen Sauter, Dr, Director Quality Assurance, Vetter Pharma Fertigung GmbH & Co. KG

  • End of Conference Day 1 & Networking Event

Thursday, 16 May CEST

  • Registration Open

  • Session 3, Track A: Environmental Monitoring

    • Moderator: Hue Kwon, PhD, Advisory consultant, GLS Advisors LLC

    This session will cover the latest developments in environmental monitoring (EM). The presenters will discuss how the data is utilized to adapt the new and updated approach for a better EM including the improvements enhanced to be compliant with Annex 1. The session will address new innovative ways to evaluate real time continuous air monitoring. Two case studies will be presented, lesson learn from implementing total particle count tubing qualification on non-viable particle count systems and Automated Reading of Agar Plates using AI. Attendees will gain insights into the latest techniques in EM, associated challenges and learnings, and how these advancements can be applied to impact our industry.
    • Total Particle Count – Tubing Qualification at GSK: Lessons Learned

      • Co-Presenter: Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

      • Co-Presenter: Kurt Jaecques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK

    • How to Collect All EM Data and Doing Computerized Trending Without Entering the Data Manually

      • Co-Presenter: Marc M. Machauer, OEM Coordinator, Particle Measuring Systems

      • Co-Presenter: Susan B. Cleary, EMBA, Director of Product Development, Novatek International

    • Automated Reading of Agar Plates Using AI and Machine Learning

      • Presenter: Andrew Gravett, Principal Scientist Microbiology, AstraZeneca

    • Q&A, Discussion

      • Moderator: Hue Kwon, PhD, Advisory consultant, GLS Advisors LLC

      • Panelist: Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

      • Panelist: Marc M. Machauer, OEM Coordinator, Particle Measuring Systems

      • Panelist: Andrew Gravett, Principal Scientist Microbiology, AstraZeneca

      • Panelist: Susan B. Cleary, EMBA, Director of Product Development, Novatek International

  • Session 3, Track B: Equipment for Aseptic Processes

    • Moderator: David Keen, MRSB CBiol, Director Pharmaceutical Microbiology & Consulting, Ecolab Life Sciences

    • Annex 1 and 'Good Technology Practice' - Interpretation and Engineering for This Side of Production

      • Presenter: Johannes M. Rauschnabel, PhD, Director Advanced Technology Development and Innovation, Syntegon Technology GmbH

    • Critical Factors in the Material Transfer Process

      • Presenter: Anna Campanella, PhD, Global Aseptic Processing & Sterility Assurance Lead, Takeda Pharmaceuticals International AG

    • Title to be announced

      • Presenter: David Keen, MRSB CBiol, Director Pharmaceutical Microbiology & Consulting, Ecolab Life Sciences

    • Q&A, Discussion

      • Moderator: Tracy Moore, Director, TM Pharma Group Ltd

      • Panelist: Anna Campanella, PhD, Global Aseptic Processing & Sterility Assurance Lead, Takeda Pharmaceuticals International AG

      • Panelist: Johannes M. Rauschnabel, PhD, Director Advanced Technology Development and Innovation, Syntegon Technology GmbH

      • Panelist: David Keen, MRSB CBiol, Director Pharmaceutical Microbiology & Consulting, Ecolab Life Sciences

  • Networking Coffee Break, Poster Session & Exhibition

    Saal MARITIM & Lobby Empore

  • Session 4, Track A: Quality Risk Management

    Alte Stuttgarter Reithalle

    • Moderator: Richard Denk, Senior Consulting Aseptic Processing & Containment, SKAN AG

    Concerning the EU GMP Annex 1, QRM Quality Risk Management includes the Contamination Control Strategy CCS with all procedures and processes for the safe production of the sterile pharmaceutical product. An essential component of quality risk management is the ICH Q9 to identify the possible risks in the production of the sterile product and to integrate them into the contamination control strategy. In the Aseptic Process Simulation APS, the entire process is checked by all operators to ensure the sterility of the pharmaceutical drug.
    • A Matter of Uncertainty: Risk Tool Selection With ICH Q9(R1) In Mind

      • Presenter: Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

    • Using Risk Management to Design Aseptic Process Simulations

      • Presenter: Alberto Gonzalez, Global Sterility Assurance Associate Director, Takeda

    • Q&A, Discussion

      • Moderator: Richard Denk, Senior Consulting Aseptic Processing & Containment, SKAN AG

      • Panelist: Alberto Gonzalez, Global Sterility Assurance Associate Director, Takeda

      • Panelist: Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

  • Session 4, Track B: RABS/Isolator

    • Moderator: Tracy Moore, Director, TM Pharma Group Ltd

    • APS for Gloveless Isolator Filling Line - Experience and Lessons Learned with the First Installation in Germany

      • Presenter: Thorsten Haefner, MBA, Vice President of Business Development, PSM GmbH

    • Leveraging Emerging Technologies for H2O2 Bio-Decontamination: From Novel Process Data to Real Process Impact

      • Presenter: Martin Novak, MSc, Technology Lead, SKAN AG

    • Q&A, Discussion

      • Moderator: Tracy Moore, Director, TM Pharma Group Ltd

      • Panelist: Thorsten Haefner, MBA, Vice President of Business Development, PSM GmbH

      • Panelist: Martin Novak, MSc, Technology Lead, SKAN AG

  • Networking Lunch Break, Poster Session & Exhibition

    Saal MARITIM & Lobby Empore

  • Interactive Questionnaire Session

    Alte Stuttgarter Reithalle

  • Closing Plenary Part I

    Alte Stuttgarter Reithalle

    • Moderator: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

    • Excitement @Syntegon – Insights and Preparation for the Syntegon Factory Tour

      • Presenter: Klaus Ullherr, Senior Product Manager, Syntegon Technology GmbH

    • Introduction of PDA PtC for Aseptic Filling

      • Presenter: Julian Petersen, Head of Business Development, groninger & co. gmbh

    • Evolution of GMPs and Why They Are Particularly Important for Sterile Manufacturing

      • Presenter: Andrew D. Hopkins, BSC Hons, PGDip, Director, Operation Quality QA Audit and Compliance, AbbVie Inc.

  • Networking Coffee Break, Poster Session & Exhibition

    Saal MARITIM & Lobby Empore

  • Passport Raffle

    Alte Stuttgarter Reithalle

  • Closing Plenary Part II

    Alte Stuttgarter Reithalle

    • Moderator: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

    • Remote presentation title to be announced

      • Regulatory Presenter: Brooke K. Higgins, MS, Branch Chief, OC, CDER, U.S. FDA

    • Remote presentation to be announced

      • Regulatory Presenter: Roberto Conocchia, MD, GMP Technical Lead, European Medicine Agency

    • Q&A, Panel Discussion

      • Moderator: Simone Biel, PhD, Senior Regulatory Consultant, Merck

      • Moderator: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

      • Panelist: Julian Petersen, Head of Business Development, groninger & co. gmbh

      • Panelist: Andrew D. Hopkins, BSC Hons, PGDip, Director, Operation Quality QA Audit and Compliance, AbbVie Inc.

      • Panelist: Roberto Conocchia, MD, GMP Technical Lead, European Medicine Agency

      • Panelist: Brooke K. Higgins, MS, Branch Chief, OC, CDER, U.S. FDA

  • Conference Summary from the Co-Chairs

    Alte Stuttgarter Reithalle

    • Co-Chair: Simone Biel, PhD, Senior Regulatory Consultant, Merck

    • Co-Chair: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

  • Closing Remarks & Farewell

    Alte Stuttgarter Reithalle

    • Committee Member: Falk Klar, PhD, Parenteral Drug Association

Presenters

  • Darren Beckett

    Sr. Training and R&D Manager, Fedegari Technologies Inc

    Co-Chair
    Moderator
    Read Bio
  • Simone Biel, PhD

    Senior Regulatory Consultant, Merck

    Co-Chair
    Moderator
    Read Bio
  • Anna Campanella, PhD

    Global Aseptic Processing & Sterility Assurance Lead, Takeda Pharmaceuticals International AG

    Panelist
    Presenter
    Read Bio
  • Tarik Cheema, PhD

    End to End Contamination Control Manager, F. Hoffmann-La Roche AG

    Panelist
    Presenter
  • Susan B. Cleary, EMBA

    Director of Product Development, Novatek International

    Co-Presenter
    Panelist
    Read Bio
  • Roberto Conocchia, MD

    GMP Technical Lead, European Medicine Agency

    Panelist
    Regulatory Presenter
    Read Bio
  • Melanie Decker

    Parenteral Drug Association

    Moderator
  • Marisa Delbo, PharmD

    Consultant , NA

    Panelist
    Regulatory Presenter
    Read Bio
  • Richard Denk

    Senior Consulting Aseptic Processing & Containment, SKAN AG

    Committee Member
    Moderator
    Read Bio
  • Paul Devuyst, Master Bioengineer

    Senior Manager Aseptic Technologies, GSK

    Committee Member
    Co-Presenter
    Moderator
    Panelist
    Read Bio
  • Rainer Glöckler

    Swissfillon - a Ten23 Health Company

    Committee Member
    Read Bio
  • Alberto Gonzalez

    Global Sterility Assurance Associate Director, Takeda

    Panelist
    Presenter
    Read Bio
  • Andrew Gravett

    Principal Scientist Microbiology, AstraZeneca

    Panelist
    Presenter
    Read Bio
  • Manuel Grund

    Process Engineer, Roche Pharmaceuticals

    Panelist
    Presenter
    Read Bio
  • Thorsten Haefner, MBA

    Vice President of Business Development, PSM GmbH

    Panelist
    Presenter
    Read Bio
  • Michael Hell, PhD

    Head of Environment / Sustainability Healthcare Operations, Merck Healthcare KGaA

    Panelist
    Presenter
    Read Bio
  • Brooke K. Higgins, MS

    Branch Chief, OC, CDER, U.S. FDA

    Panelist
    Regulatory Presenter
    Read Bio
  • Andrew D. Hopkins, BSC Hons, PGDip

    Director, Operation Quality QA Audit and Compliance, AbbVie Inc.

    Panelist
    Presenter
    Read Bio
  • Kurt Jaecques, MA

    Global Aseptic Technologies Lead Monitoring & Control, GSK

    Co-Presenter
    Read Bio
  • Hussain Jafri, PhD

    Executive Director , World Patients Alliance

    Panelist
    Presenter
    Read Bio
  • David Keen, MRSB CBiol

    Director Pharmaceutical Microbiology & Consulting, Ecolab Life Sciences

    Committee Member
    Moderator
    Panelist
    Presenter
    Read Bio
  • Falk Klar, PhD

    Parenteral Drug Association

    Committee Member
    Read Bio
  • Hue Kwon, PhD

    Advisory consultant, GLS Advisors LLC

    Committee Member
    Moderator
    Read Bio
  • Yuan-An Liu, PhD

    Associate Director CMC, BioNTech SE

    Panelist
    Presenter
    Read Bio
  • Marc M. Machauer

    OEM Coordinator, Particle Measuring Systems

    Co-Presenter
    Panelist
    Read Bio
  • Peter J. Makowenskyj, MEng

    Director of Design Consulting, G-CON

    Committee Member
    Moderator
    Read Bio
  • Amanda McFarland, MS

    Senior Consultant, ValSource, Inc.

    Panelist
    Presenter
    Read Bio
  • Christina Meissner

    AGES - Austrian Agency for Health and Food Safety

    Panelist
    Regulatory Committee Member
    Regulatory Presenter
    Read Bio
  • Alissa Monk

    Sustainability Lead , ten23 health

    Panelist
    Presenter
    Read Bio
  • Tracy Moore

    Director, TM Pharma Group Ltd

    Committee Member
    Moderator
    Panelist
    Presenter
    Read Bio
  • Daniel Mueller, PhD

    Head of GMDP-Inspectorate, Regierungspraesidium Tuebingen, Germany

    Panelist
    Regulatory Presenter
    Read Bio
  • Martin Novak, MSc

    Technology Lead, SKAN AG

    Panelist
    Presenter
    Read Bio
  • Julian Petersen

    Head of Business Development, groninger & co. gmbh

    Panelist
    Presenter
    Read Bio
  • Johannes M. Rauschnabel, PhD

    Director Advanced Technology Development and Innovation, Syntegon Technology GmbH

    Panelist
    Presenter
    Read Bio
  • Christian Rust, B.S. Chemical and Biomolecular Engineering

    Technical Operations, MSD

    Panelist
    Presenter
    Read Bio
  • Andrea Salmaso, PharmD

    Corporate Regulatory and Scientific Affairs Manager, Stevanato Group

    Committee Member
    Moderator
    Read Bio
  • Helen Sauter, Dr

    Director Quality Assurance, Vetter Pharma Fertigung GmbH & Co. KG

    Committee Member
    Panelist
    Presenter
    Read Bio
  • Christian Scarpato

    Process Engineering Manager, Merck

    Panelist
    Presenter
    Read Bio
  • Klaus Ullherr

    Senior Product Manager, Syntegon Technology GmbH

    Committee Member
    Moderator
    Presenter
    Read Bio

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.

 The booking cut-off date is 1 February 2024.
How to Get Here
By Air Unlock discounted pricing with the following code DEAPILX and simply use the provided link below.
By Other Options By Train: Unlock discounted pricing and simply use the provided link below.